Owkin licenses K Pro AI Scientist plus multimodal oncology and immunology patient data to Boehringer Ingelheim

Owkin does the enrichment on both sides of the deliverable: it has already built the MOSAIC multimodal oncology substrate (expanding toward 7,000 patients across seven cancer indications per the Pharma Letter profile) and will generate new immunology multimodal data through its patient-data network, and it is Owkin's K Pro reasoning layer that is being licensed as the environment for analysis.

The payer here is Boehringer Ingelheim, and the decision the substrate is pointed at is which oncology and immunology targets and hypotheses to carry forward in a pipeline that already includes assets like zongertinib and obrixtamig; MOSAIC's spatial transcriptomics, scRNA-seq, WES and digitised H&E layers are what make that target-triage call tractable, as evidenced by the 2025 pilot that returned spatial tumour-microenvironment insight on a specific Boehringer gene target.

By the author's Owkin/Servier ruling this reads as sell rather than wrap: the press release explicitly says Owkin will license multimodal oncology data to Boehringer and generate new immunology data for it, so the data is the deliverable even though it is reached through K Pro. What stays on Owkin's side of the boundary is the MOSAIC generation pipeline and the K Pro codebase itself; what crosses is licensed access to the dataset and to the reasoning environment used to interrogate it, inside Boehringer's R&D.

Not determinable from public facts: the licence fee, term and any downstream economics (milestones, royalties on discoveries made via K Pro) are undisclosed, so whether Owkin priced the substrate against the value Boehringer will extract across an 80-plus-project pipeline cannot be read from the announcement.